[COMPARISON OF DIFFERENT TREATMENT REGIMENS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE]

To compare the effectiveness of different treatment strategies of nonalcoholic fatty liver disease.

51 patients with nonalcoholic steatohepatitis (NASH) were included in an open randomized prospective comparative study with no control. Patients were divided into 2 groups depending on the chosen treatment strategy. Group 1 (n = 25) had been receiving standard treatment of NASH (Ursodeoxycholic acid 15 mg/kg once a day, per os divided into 3 doses, Atorvastatin 20 mg per os at night, Vitamin E 800 IU/day per os for 12 months); Group 2 (n = 26) had been receiving losartan 50 mg/day per os for 12 months in addition to the above mentioned standard treatment of NASH.

In overall, the results of this work suggest that long-term, for 12 months, losartan usage in a daily dose of 50 mg in the complex therapy of patients with NASH is followed by a significant decrease in the levels of tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6) in serum and improvement in 13C-metathetin breath test results. These results indicate a decrease in inflammation and slowing of formation and regression of liver fibrosis. Absence of progress in liver fibrosis in patients on losartan treatment was revealed.

Additional inclusion of losartan in the standard therapy of NASH has a positive therapeutic effect on the process of fibrogenesis in the liver, so it is advisable to appoint losartan in a daily dose of 50 mg for 1 year to these patients.